What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question

A relevant issue on the treatment of adrenocortical carcinoma (ACC) concerns the optimal duration of adjuvant mitotane treatment. We tried to address this question, assessing whether a correlation exists between the duration of adjuvant mitotane treatment and recurrence-free survival (RFS) of patien...

Full description

Bibliographic Details
Main Authors: Vittoria Basile, Soraya Puglisi, Barbara Altieri, Letizia Canu, Rossella Libè, Filippo Ceccato, Felix Beuschlein, Marcus Quinkler, Anna Calabrese, Paola Perotti, Paola Berchialla, Ulrich Dischinger, Felix Megerle, Eric Baudin, Isabelle Bourdeau, André Lacroix, Paola Loli, Alfredo Berruti, Darko Kastelan, Harm R. Haak, Martin Fassnacht, Massimo Terzolo
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Journal of Personalized Medicine
Subjects:
mitotane
adjuvant treatment
adrenocortical cancer
recurrence
recurrence free survival
timing
Online Access:https://www.mdpi.com/2075-4426/11/4/269

Internet

https://www.mdpi.com/2075-4426/11/4/269

Similar Items